Low dose of sodium-glucose transporter 2 inhibitor ipragliflozin attenuated renal dysfunction and interstitial fibrosis in adenine-induced chronic kidney disease in mice without diabetes.

•Chronic kidney disease (CKD) was induced by adenine containing diet in mice.•Low doses of SGLT2 inhibitor ipragliflozin was administered to CKD mice.•These low doses did not affect plasma glucose levels or urinary glucose excretion.•These low doses attenuated renal dysfunction and interstitial fibrosis in CKD mice.•The direct anti-inflammatory and anti-oxidant effect might account for this effect.